|1.||Adrian, Thomas E: 6 articles (01/2008 - 10/2002)|
|2.||Ding, Xian-Zhong: 5 articles (06/2007 - 10/2002)|
|3.||Hennig, Rene: 4 articles (01/2008 - 10/2002)|
|4.||Tong, Wei-Gang: 3 articles (06/2007 - 10/2002)|
|5.||Bell, Richard H: 3 articles (06/2007 - 04/2005)|
|6.||Talamonti, Mark S: 2 articles (06/2007 - 04/2005)|
|7.||de Alwis, Dinesh P: 2 articles (06/2007 - 08/2005)|
|8.||Budman, Daniel R: 2 articles (08/2005 - 10/2004)|
|9.||Jovanovic, Borko D: 2 articles (04/2005 - 07/2004)|
|10.||Witt, Richard C: 2 articles (07/2004 - 10/2002)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
06/01/2005 - "Recent studies have shown that an orally stable leukotriene (LT) B4 receptor antagonist, LY293111, has a potent anti-pancreatic cancer effect. "
01/01/2008 - "LY293111 was shown to have potent anticancer effects in pancreatic cancer and several other solid malignancies, where it caused cell cycle arrest and marked apoptosis. "
06/01/2007 - "In conclusion, LY293111 induces apoptosis in human pancreatic cancer cells through the mitochondria-mediated pathway. "
06/01/2005 - "A novel anti-pancreatic cancer agent, LY293111."
10/01/2002 - "The effects of leukotriene (LT) B4 and its receptor antagonist LY293111 on proliferation and apoptosis of human pancreatic cancer cells were investigated, both in vitro and in vivo. "
10/01/2002 - "In studies using AsPC-1 and HPAC cell xenografts in athymic mice, LY293111 treatment markedly inhibited tumor growth over a 24-day treatment period, as measured by both tumor volume and tumor weight. "
06/01/2005 - "This review summarizes the current research status of LY293111 as an anti-cancer agent with a focus on pancreatic cancer."
08/10/2005 - "Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors."
07/08/2004 - "The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. "
06/01/2005 - "LY293111 inhibits pancreatic cancer growth, induces tumor cell apoptosis both in vitro and in vivo, and enhances the anti-pancreatic cancer effect of gemcitabine. "
09/01/1998 - "Although not statistically significant, a tendency for the increased expression of some markers of cutaneous inflammation and epidermal proliferation was observed after 1 week of treatment with VML295, and a decreased expression of these markers was seen after 4 weeks of treatment with VML295. "
04/04/1997 - "LY293111 proved to be a potent inhibitor of LTB4-induced cutaneous inflammation and hyperproliferation. "
12/01/1996 - "The effect of the novel LTB4 receptor antagonist, LY293111, was examined using allergen challenge as a model for asthmatic inflammation in 12 atopic asthmatic subjects in a double blind placebo controlled crossover trial. "
|4.||Psoriasis (Pustulosis Palmaris et Plantaris)
09/01/1998 - "VML295 in the treatment of chronic plaque psoriasis was shown to be safe and well tolerated. "
09/01/1998 - "The aim of the present study was to investigate the efficacy and clinical tolerability of the specific leukotriene B4 receptor antagonist VML295 in the treatment of stable plaque psoriasis. "
|5.||Neoplasm Metastasis (Metastasis)
|2.||Leukotriene B4 Receptors (Leukotriene B4 Receptor)
|7.||Benzoic Acid (Ucephan)
|9.||Proteins (Proteins, Gene)
|10.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|1.||Heterologous Transplantation (Xenotransplantation)